Login

Allergan plc 8-K SEC Filings

Filed On Filing
14 May 2020 8-K: Material Modification to Rights of Security Holders

On May 14, 2020 (the “Settlement Date”), AbbVie Inc. (“AbbVie”) completed its previously announced (i) offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) any and all outstanding notes of certain serie...

08 May 2020 8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +5 more

The Company is a public limited company deemed to be a PLC to which Part 17 of the Companies Act 2014 applies.

06 May 2020 8-K: Other Events

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

21 Apr 2020 8-K: Temporary Suspension of Trading Under Employee Benefit Plans; Other Events

A. Robert D. Bailey, Executive Vice President & Chief Legal Officer

18 Mar 2020 8-K: Other Events

NORTH CHICAGO, Ill. and DUBLIN, March 17, 2020/PRNewswire/ – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that they have en...

03 Mar 2020 8-K: Other Events

NORTH CHICAGO, Ill. and DUBLIN, March 3, 2020 /PRNewswire/ – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the European...

10 Feb 2020 8-K: Results of Operations and Financial Condition

- Full-Year 2019 GAAP Net Revenues of $16.1 Billion; Q4 2019 GAAP Net Revenues of $4.4 Billion -

27 Jan 2020 8-K: Other Events

Agreements Contingent on FTC and European Commission Approval and Completion of AbbVie’s Pending Acquisition of Allergan

05 Nov 2019 8-K: Results of Operations and Financial Condition

Non-GAAP Net revenues grew 3.6% to $4,026M versus prior year.

05 Nov 2019 8-K: Results of Operations and Financial Condition

- Q3 2019 GAAP Loss Per Share of $2.40; Non-GAAP Performance Net Income Per Share of $4.25 -

15 Oct 2019 8-K: Submission of Matters to a Vote of Security Holders; Other Events

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

27 Sep 2019 8-K: Other Events

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

16 Sep 2019 8-K: Regulation FD Disclosure

We report on the profit forecast comprising the statement by Allergan plc (“Allergan”) and its subsidiaries (together the “Allergan Group”) in respect of non-GAAP Net Income per share for the year ending 31 December 2019 (the “Profit For...

11 Sep 2019 8-K: Other Events

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

06 Aug 2019 8-K: Results of Operations and Financial Condition

GAAP Net revenues grew 0.6% and non-GAAP Net revenues grew 1.2% to $4,090M.

06 Aug 2019 8-K: Results of Operations and Financial Condition

– Q2 2019 GAAP Loss Per Share of $5.37; Non-GAAP Performance Net Income Per Share of $4.38 –

25 Jun 2019 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

07 May 2019 8-K: Results of Operations and Financial Condition

-- Q1 2019 GAAP Loss Per Share of $7.25; Non-GAAP Performance Net Income Per Share of $3.79 --

01 May 2019 8-K: Submission of Matters to a Vote of Security Holders

On May 1, 2019, Allergan plc (the “Company” or “Allergan”) held its 2019 Annual General Meeting of Shareholders (the “AGM”) in Dublin, Ireland. There were 332,730,264 ordinary shares of Allergan outstanding as of March 5, 2019, the recor...

22 Mar 2019 8-K: Other Events

On March 22, 2019, Allergan plc (“Allergan”) filed its 2019 definitive proxy materials with the Securities and Exchange Commission in connection with the Company’s Annual General Meeting of Shareholders to be held on May 1, 2019, which i...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support